EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • December 3rd, 2018 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Exclusive Patent License Agreement (this “Agreement”), is entered into as of November 30, 2018 (the “Effective Date”), by and between Allergan, Inc., a Delaware corporation (“Allergan”) and Aclaris Therapeutics, Inc., a Delaware corporation (“Licensee”). Allergan and Licensee are each referred to herein by name or as a “Party” or, collectively, as the “Parties.” Capitalized terms used but not defined herein shall have the meanings otherwise ascribed to them in the Purchase Agreement (as defined below).
ASSET PURCHASE AGREEMENT by and between ACLARIS THERAPEUTICS, INC., as Buyer and ALLERGAN SALES, LLC, as Seller dated as of October 15, 2018 Confidential and Proprietary CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY...Asset Purchase Agreement • December 3rd, 2018 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AGREEMENT is entered into as of October 15, 2018 (this “Agreement”), by and among Aclaris Therapeutics, Inc., a Delaware corporation (“Buyer”), and Allergan Sales, LLC, a Delaware limited liability company (“Seller”).
